A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin

The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in
comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of
treatment, followed by an extension.

The primary objective is to assess the effects of lixisenatide when added to metformin on
glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction when it is used in two
steps dose titration regimen at Week 24.

Secondary objectives are to assess the effects of lixisenatide when added to metformin on
glycemic control in comparison to placebo in terms of HbA1c reduction when it is used in a
one-step dose titration regimen, the percentage of patients with HbA1c less than 7 percent or
less than or equal to 6.5%, body weight, fasting plasma glucose (FPG); to assess the safety,
tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.